Here's Why Selecta Biosciences Is Tumbling Today
A licensing deal for a late-stage asset failed to impress Wall Street. One analyst went as far as downgrading the biopharma stock.
2 Top Small-Cap Stocks to Buy Right Now
Volatile stock market or not, these two drug developers are well positioned for long-term success.
Here's Why Alliance Resource Partners Fell as Much as 13.5% Today
The Fed thinks the economy will take more time to recover than Wall Street was expecting, which is bad news for this coal stock.
Here's Why Invitae Fell as Much as 10.1% Today
The growth stock is an easy target in a volatile market.
Here's Why Renewable Energy Group Dropped Over 10% Today
The small-cap stock hit an all-time high earlier this month, but gloomy economic outlooks have investors rethinking the company's valuation.
New Gold Rises as Much as 12.9% on Series of Financing Deals
The gold miner is making moves to improve its near-term financial flexibility.
Here's Why Albemarle Gained 24.6% in May
The world's leading lithium producer benefitted from rising confidence about the pace of a possible economic recovery.
Here's Why AnaptysBio Rose 22.1% in May
The beaten-up biopharma provided an update that revved up interest in its pipeline.
Here's Why CymaBay Therapeutics Rose 109% in May
The development-stage company might be able to resume the development of its lead drug candidate, which was halted in late 2019.
Here's Why Athersys Rose 26.5% in May
The stem cell stock recovered from a lousy April as the company fed investors updates for its COVID-19 programs.
Here's Why TG Therapeutics Jumped 58.6% in May
The development-stage company appears to be on the path to commercial operations.
Here's Why Fate Therapeutics Rose 18.4% in May
The cell therapy developer announced the next step for an important pipeline asset.
2 Top Growth Stocks to Buy in June
The stock market is expensive, but these two energy stocks have long-term tailwinds supporting their growth strategies.
The Next Big Obstacle in Renewable Energy Is a Big Opportunity for Investors
The United States could add a record 33,000 megawatts of renewables to the grid in 2020, but a record build out of transmission will be needed to keep growth humming along.
The Debate Is Over: This Cancer Stock Is Winning the GIST Race
Blueprint Medicines and Deciphera Pharmaceuticals were going toe-to-toe developing treatments for this rare cancer. Investors can now call the winner.
Party Like It's 1880: Renewable Energy Consumption Surpasses Coal
The last time the feat was accomplished, the United States relied primarily on wood for energy. There's no turning back now.
Here's Why Amyris Is Soaring Today
A bullish article is pushing shares higher, but investors need to remain grounded.
Here's Why Intellia Therapeutics Gained as Much as 18.0% Today
An existing partner is doubling down on the gene editing platform.
Is Catalent a Buy?
A combination of acquisitions and coronavirus vaccine manufacturing deals have pushed shares to an all-time high, but not all earnings are flowing to common stockholders.
2 Stats Show the Dire State of U.S. Coal-Fired Power Plants
The first-quarter performance of America's dirtiest power source was the worst in decades, but there are opportunities in coal's demise.